Ionis Highlights Positive Zilganersen Data in Alexander Disease

Ionis Pharmaceuticals ( (IONS) ) has provided an announcement.

On April 21, 2026, Ionis reported additional positive data from a pivotal Phase 1-3 study of its investigational RNA-targeted drug zilganersen in children and adults with Alexander disease, a rare, progressive and often fatal neurological disorder lacking disease-modifying treatments. The 60-week randomized trial met its primary endpoint in patients aged five and older, with the 50 mg dose showing statistically significant and clinically meaningful stabilization of gait speed on the 10-Meter Walk Test versus control at Week 61.

Supporting data from the Gross Motor Function Measure-88 indicated that zilganersen may improve gross motor function in children aged two to four, while multiple patient-, caregiver- and clinician-reported secondary endpoints consistently favored the drug over control across symptom severity and overall health. The therapy demonstrated a favorable safety and tolerability profile, reduced plasma GFAP levels in exploratory analysis, and is under U.S. FDA Priority Review with a Prescription Drug User Fee Act decision scheduled for September 22, 2026, potentially positioning Ionis as a first mover in treating Alexander disease and offering new hope to an underserved patient community.

The most recent analyst rating on (IONS) stock is a Buy with a $110.00 price target. To see the full list of analyst forecasts on Ionis Pharmaceuticals stock, see the IONS Stock Forecast page.

Spark’s Take on IONS Stock

According to Spark, TipRanks’ AI Analyst, IONS is a Neutral.

The score is held back primarily by weak financial performance (ongoing losses, cash burn, and higher leverage) and bearish technical momentum. These are partly offset by a positive earnings-call outlook featuring improving revenue trajectory and meaningful pipeline/launch catalysts, though continued large expected operating losses and timing risks limit the upside in the near term.

To see Spark’s full report on IONS stock, click here.

More about Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc., based in Carlsbad, Calif., is a biotechnology company specializing in RNA-targeted medicines. Its pipeline includes investigational therapies like zilganersen aimed at treating rare, severe neurological diseases with high unmet medical need, targeting underlying genetic drivers of disease.

Average Trading Volume: 2,225,208

Technical Sentiment Signal: Buy

Current Market Cap: $12.69B

See more data about IONS stock on TipRanks’ Stock Analysis page.